Phase 2 Alzheimer's Disease Trial, Recruiting NCT06718686 Sponsor: Jasmohan Bajaj Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 2 Alzheimer's Disease Trial, Recruiting

NCT06718686
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with probable Alzheimer's Disease or Vascular Dementia that is rated as mild or moderate in severity.
  • People aged 65 years or older, of any gender.
  • People who live in the community (not in a care facility) and have a caregiver who is able to attend study visits with them and take part in the study.
  • People who are able to give their own consent, or who have a legal guardian who can consent on their behalf (with the person's agreement).
  • People whose legal guardian and caregiver are the same person.
  • People, along with their caregiver, who can read and speak English well enough to take part in study visits.

Who may not be able to join:

  • People whose dementia is caused by something other than Alzheimer's Disease or Vascular Dementia.
  • People who have significant agitation or aggression that requires treatment with antipsychotic medication.
  • People who experience delusions (false beliefs) or hallucinations (seeing or hearing things that aren't there).
  • People with serious mental health conditions, including severe depression.
  • People with unstable, severe, or poorly managed medical conditions identified through physical examination or medical history.
  • People with a vision or hearing problem that would prevent them from completing memory and thinking tests.
  • People who currently have diarrhea.
  • People who have a known allergy or sensitivity to rifaximin, any of its ingredients, or related antibiotic medicines called rifamycins.
  • People who have taken antibiotics in the past 6 months.
  • People who are taking medications that are known to interact with rifaximin (note: certain medications called P-glycoprotein inhibitors may be permitted if discussed with the study doctor).
  • People with a history of alcohol or drug misuse.
  • People who have taken part in another clinical drug trial within the last 30 days.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jasmohan Bajaj, Richmond VA Medical Center

Phone: 804-675-5802

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Jasmohan Bajaj
Registry
ClinicalTrials.gov
Start date
30 December 2024
Est. completion
30 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in stool and serum short-chain fatty acid levels; Change in bile acids in stool and serum

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov